Image

Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage

Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.

Description

Spontaneous deep intracerebral hemorrhage (ICH) is associated with high early mortality and long-term disability. Conventional craniotomy has not consistently improved functional outcomes, while medical management alone often results in poor prognosis. Minimally invasive surgery (MIS), including parafascicular approaches guided by neuronavigation, is designed to evacuate hematomas with reduced disruption of critical white-matter tracts. Evidence supporting MIS is more robust in lobar ICH, whereas data for basal ganglia hemorrhage remain limited. Furthermore, most prior studies restricted surgical intervention to within 24 hours from onset, leaving uncertainty regarding potential benefit when performed between 24 and 72 hours.

This prospective, multicenter, observational cohort study is conducted at People's Hospital 115 and Tam Anh General Hospital. Consecutive patients admitted with spontaneous basal ganglia ICH are enrolled within 72 hours of onset. Decisions regarding MIS, including whether to operate and the timing of surgery, are made by treating clinical teams in routine practice. The study does not assign interventions but documents real-world management and outcomes.

Data are captured prospectively using standardized CRFs and electronic CRFs. Information includes demographics, comorbidities, presenting neurological status, laboratory and imaging findings, details of MIS when performed, intensive care and hospital course, and follow-up assessments through 180 days. The primary endpoint is functional outcome at 180 days, while safety endpoints include mortality and treatment-related complications. Analyses are planned using prespecified multivariable approaches to account for confounding by indication. Additional subgroup analyses will assess outcomes by timing of MIS (0-24 vs 24-72 hours) and other clinically relevant variables.

By focusing on basal ganglia hemorrhage in contemporary Vietnamese stroke centers, this study is intended to generate real-world evidence on the effectiveness and safety of MIS in deep ICH and inform selection criteria and timing for future interventional trials.

Eligibility

Inclusion Criteria:

  • Age 18 to 80 years
  • Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT scan
  • Hematoma volume 30-80 mL (ABC/2 method)
  • Time from onset/last known well ≤ 72 hours
  • Glasgow Coma Scale (GCS) score 5-14 at admission
  • Pre-stroke modified Rankin Scale (mRS) score 0-1

Exclusion Criteria:

  • Secondary intracerebral hemorrhage due to trauma, tumor, vascular malformation, aneurysm, or hemorrhagic transformation of ischemic stroke
  • Infratentorial hemorrhage (brainstem or cerebellum)
  • Primary thalamic hemorrhage
  • Extensive intraventricular hemorrhage (\>50% of one lateral ventricle)
  • NIHSS \< 5 at admission
  • Bilateral fixed dilated pupils without light reflex
  • Decerebrate posture
  • Platelet count \< 75,000/µL
  • INR \> 1.4 after correction
  • Ongoing anticoagulation that cannot be rapidly reversed
  • Indication for long-term anticoagulation within 5 days of onset
  • End-stage renal disease
  • End-stage liver disease
  • Presence of mechanical heart valve
  • Any comorbidity with life expectancy \< 6 months
  • Patient or legal representative unwilling or unable to provide written informed consent

Study details
    Intracerebral Hemorrhage Basal Ganglia
    Intracerebral Haemorrhage

NCT07234955

Huynh Quoc Huy

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.